AbbVie Inc (ABBV)

$216.31-1.06%
Spriggl Score: Moderate— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict

Dividend compounder beating and raising every quarter; Skyrizi +30.9% with patent runway to 2033. Reasonable 14x forward P/E and 3.3% yield — debt load the only structural concern.

Sign up free to read the full investment thesis, bull case, bear case and what to watch.

About AbbVie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvi

Sector:
Healthcare
Industry:
Drug Manufacturers - General
Market Cap:
$372.4B

Recent dividends

  • 15 Apr 2026$1.73
  • 16 Jan 2026$1.73
  • 15 Oct 2025$1.64

Get the full Spriggl analysis — free

Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on AbbVie Inc and 1,600+ UK and US stocks.

Start free